Safety of the rifampin and pyrazinamide short-course regimen for treating latent tuberculosis infection.
Ijaz
Kashef
K
McElroy
Peter D
PD
Jereb
John
J
Navin
Thomas R
TR
Castro
Kenneth G
KG
D000995:Antitubercular Agents / Q000009:adverse effects*; D004334:Drug Administration Schedule; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology; D017410:Practice Guidelines as Topic; D011718:Pyrazinamide / Q000009:adverse effects*; D012293:Rifampin / Q000009:adverse effects*; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy*
D000995:Antitubercular Agents; D011718:Pyrazinamide; D012293:Rifampin